Business Context and Reporting Period
Company: GlaxoSmithKline plc (GSK)
Filing Type: Form 6-K (Report of Foreign Issuer)
Reporting Period: Second Quarter ended 30 June 2005 (Q2 2005) and First Half 2005 (H1 2005)
Accounting Basis: International Financial Reporting Standards (IFRS)
Key Context: GSK reported strong financial performance driven by key pharmaceutical products and a robust pipeline. The company transitioned to IFRS reporting effective 1 January 2005, resulting in presentational changes such as reclassifying legal costs into Selling, General, and Administrative (SG&A) expenses.
Key Financial Metrics
| Metric | Q2 2005 (£m) | Q2 2004 (£m) | CER Growth % | H1 2005 (£m) | H1 2004 (£m) | CER Growth % |
|---|---|---|---|---|---|---|
| Turnover | 5,246 | 4,971 | 6% | 10,282 | 9,826 | 5% |
| Operating Profit | 1,711 | 1,525 | 13% | 3,458 | 3,018 | 16% |
| Profit Before Tax | 1,662 | 1,540 | 9% | 3,373 | 3,006 | 13% |
| Profit After Tax | 1,189 | 1,114 | 8% | 2,412 | 2,174 | 12% |
| Earnings Per Share (Basic) | 20.4p | 18.9p | 10% | 41.5p | 36.9p | 14% |
| Operating Cash Flow | 1,530 | 1,329 | - | 2,817 | 2,390 | - |
| Net Debt | (1,261) | (2,023) | - | (1,261) | (2,023) | - |
Note: CER = Constant Exchange Rate. Net debt figures represent a net cash position (negative debt) of £1.261 billion at 30 June 2005.
Material Changes vs. Prior Period
- Revenue Growth: Total turnover increased 6% (CER) in Q2, driven by a 6% rise in Pharmaceuticals and 3% in Consumer Healthcare. Pharmaceutical growth was led by Respiratory (+13%), Metabolic (+17%), and Vaccines (+15%).
- Profitability Expansion: Operating profit grew 13% (CER) in Q2, outpacing revenue growth. Operating margin improved by 2.3 percentage points (CER) to 32.6%, primarily due to a 6% reduction in SG&A expenses (driven by lower legal charges) and improved efficiencies.
- Product Performance:
- Growers: Seretide/Advair (+22%), Avandia/Avandamet (+16%), Lamictal (+28%), and Vaccines (+15%).
- Decliners: Paxil franchise (-47%) and Wellbutrin franchise (-11%) due to generic competition and a temporary supply interruption of Paxil CR in the US.
- Cash Flow: Operating cash inflow was £1.53 billion in Q2, exceeding the funds required for routine tax, capex, and dividends.
- Balance Sheet: Net assets increased to £6.799 billion. Net debt improved significantly from £1.984 billion at year-end 2004 to a net cash position of £1.261 billion.
Guidance, Outlook, and Risks
Guidance and Outlook
- EPS Guidance: Management expects 2005 EPS percentage growth (CER) to be in the "low double-digit range."
- Dividends: A second interim dividend of 10 pence per share was declared, payable 6 October 2005.
- Share Buy-back: Under a £4 billion programme, GSK invested a further £390 million in H1 2005 to purchase Treasury shares.
- Pipeline: Strong momentum with launches of Boniva (osteoporosis) and Requip (restless legs syndrome). Five major new vaccines expected in the next five years. Aplaviroc (HIV) entered Phase III.
Risks and Contingencies
- Tax Litigation: Significant ongoing disputes with the US IRS regarding transfer pricing for years 1989–2000. Total claims amount to $7.8 billion (taxes and interest). GSK has filed counter-claims for $1.8 billion. A trial for 1989–1996 claims is scheduled for October 2006.
- Legal Provisions: Aggregate provision for legal and other disputes (excluding tax) was just over £1 billion as of 30 June 2005. Potential judgments could exceed current provisions.
- Patent Challenges: Ongoing intellectual property litigation regarding Zofran (ondansetron) patents, with appeals and trials pending in the US.
- Supply Chain: Temporary supply interruptions for Paxil CR and Avandamet in the US impacted reported sales, though market share recovery is underway.
Investor Verification Checklist
- Verify Tax Exposure: Assess the potential financial impact of the $7.8 billion IRS transfer pricing claim and the likelihood of the counter-claim success.
- Monitor Patent Litigation: Track the outcome of the Zofran patent appeals and trials, as a loss could materially affect respiratory franchise revenue.
- Track Supply Recovery: Confirm the full recovery of market share for Paxil CR and Avandamet following US supply interruptions.
- Review Pipeline Milestones: Monitor the regulatory filing dates for Cervarix (HPV vaccine) and the Phase III data readouts for Aplaviroc (HIV) and Retapamulin (antibiotic).
- Currency Sensitivity: Evaluate the impact of the strengthening US dollar (approx. $1.75/£1) on future earnings, as noted by management as a potential favorable factor.